Product Code: GVR-2-68038-315-7
Cardiac Rhythm Management Devices Market Growth & Trends:
The global cardiac rhythm management devices market size is anticipated to reach USD 24.8 billion in 2030 and is projected to grow at a CAGR of 6.4% from 2025 to 2030. The key factors driving the market include growth in the adoption of cardiac rhythm management (CRM) devices owing to the increasing prevalence of cardiovascular disorders. According to the Centers for Disease Control and Prevention (CDC), as of September 2021, approximately 659,000 Americans die suffering from heart disease every year. The market was negatively impacted during the COVID-19 pandemic, as elective procedures, including the non-essential cardiovascular procedures, were postponed or canceled during the pandemic.
Major players in the market such as Medtronic; Abbott; and Boston Scientific Corporation, incurred huge losses in their cardiac rhythm management business segments globally. This resulted in negative growth of the market in 2020. The rising demand for handling sudden cardiac arrests is leading to innovation in all types of cardiac rhythm management devices. Innovation with regards to implantable devices includes products, such as subcutaneous and transvenous devices, that aim to increase the comfort level of patients. Swedish Transport Agency ran a program under the test phase, which aimed to deliver AEDs using a drone. This may reduce the delivery time of an AED, increasing the chances of survival with faster treatment.
Therefore, the market is anticipated to grow because of technological advancements and product innovations. Revolutionary technological signs of progress are rapidly transforming the market. These expansions are producing lucrative potentials. An increase in R&D expenditure and new product launches by leading firms further fueled the growth. For instance, in October 2020, Abbott launched its new ICD and CRT-D in India, hence expanding its product portfolio in the country. The company had also received CE Mark approval for its Gallant ICD and CRT-D devices in February 2020. Such factors boost market growth. Key market players account for a significant share of the market owing to their extensive product offerings.
Cardiac Rhythm Management Devices Market Report Highlights:
- By product, defibrillators dominated the market with a share of over 44.9% in 2024 due to their high adoption globally.
- In the external defibrillator segment, the automatic external defibrillator segment held the highest revenue share owing to associated benefits, including pacing, i.e., delivering pulses of the current to stimulate heart contraction as well as cardioversion, converting arrhythmia or tachycardia to a normal heartbeat.
- In 2024, North America held the dominant share of the market owing to the rising prevalence of cardiovascular diseases and high adoption of CRM devices.
- Asia Pacific region is expected to show lucrative growth over the forecast period owing to the presence of emerging countries such as China and India.
Table of Contents
Chapter 1. Methodology And Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.2. Regional Scope
- 1.3. Estimates And Forecast Timeline
- 1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information Or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.10. List of Primary Sources
- 1.11. List of Abbreviations
Chapter 2. Cardiac Rhythm Management Devices Market: Executive Summary
- 2.1. Market Snapshot
- 2.2. Product Snapshots
- 2.3. Competitive Landscape Snapshot
Chapter 3. Cardiac Rhythm Management Devices Market Variables, Trends, & Scope
- 3.1. Market Segmentation And Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers Analysis
- 3.4.1. Growing prevalence of cardiovascular disease
- 3.4.2. Increasing preference for minimally invasive procedures
- 3.5. Market Restraint Analysis
- 3.5.1. High cost associated with the devices
- 3.6. Cardiac Rhythm Management Devices Market Analysis Tools
- 3.6.1. Industry Analysis - Porter's
- 3.6.1.1. Supplier Power
- 3.6.1.2. Buyer Power
- 3.6.1.3. Substitution Threat
- 3.6.1.4. Threat Of New Entrant
- 3.6.1.5. Competitive Rivalry
- 3.6.2. PESTLE Analysis
- 3.6.2.1. Political Landscape
- 3.6.2.2. Technological Landscape
- 3.6.2.3. Economic Landscape
- 3.6.3. Pricing Analysis
Chapter 4. Cardiac Rhythm Management Devices: Product Estimates & Trend Analysis
- 4.1. Product Market Share, 2024 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Cardiac Rhythm Management Devices Market By Product Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 To 2030 For the Following
- 4.4.1. Pacemakers
- 4.4.1.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.1.1.1. Implantable
- 4.4.1.1.1.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.1.1.2. External
- 4.4.1.1.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.2. Defibrillators
- 4.4.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.2.1.1. Implantable Cardioverter Defibrillators (ICD)
- 4.4.2.1.1.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.2.1.1.1.1.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.2.1.1.1.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.2.1.2. External Defibrillator
- 4.4.2.1.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.2.1.2.1.1. Manual External Defibrillator
- 4.4.2.1.2.1.1.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.2.1.2.1.2. Automatic External Defibrillator
- 4.4.2.1.2.1.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.2.1.2.1.3. Wearable Cardioverter Defibrillator
- 4.4.2.1.2.1.3.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.3. Cardiac Resynchronization Therapy (CRT)
- 4.4.3.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.3.1.1. CRT-Defibrillator
- 4.4.3.1.1.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 4.4.3.1.2. CRT-Pacemakers
- 4.4.3.1.2.1. Market Estimates and Forecasts 2018 To 2030 (USD Million)
Chapter 5. Regional Business Analysis
- 5.1. Regional Market Share Analysis, 2024 & 2030
- 5.2. Regional Market Dashboard
- 5.3. Global Regional Market Snapshot
- 5.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
- 5.5. North America
- 5.5.1. U.S.
- 5.5.1.1. Key Country Dynamics
- 5.5.1.2. Competitive Scenario
- 5.5.1.3. Regulatory Framework
- 5.5.1.4. U.S. Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.5.2. Canada
- 5.5.2.1. Key Country Dynamics
- 5.5.2.2. Competitive Scenario
- 5.5.2.3. Regulatory Framework
- 5.5.2.4. Canada Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.5.3. Mexico
- 5.5.3.1. Key Country Dynamics
- 5.5.3.2. Competitive Scenario
- 5.5.3.3. Regulatory Framework
- 5.5.3.4. Canada Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.6. Europe
- 5.6.1. UK
- 5.6.1.1. Key Country Dynamics
- 5.6.1.2. Competitive Scenario
- 5.6.1.3. Regulatory Framework
- 5.6.1.4. UK Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.6.2. Germany
- 5.6.2.1. Key Country Dynamics
- 5.6.2.2. Competitive Scenario
- 5.6.2.3. Regulatory Framework
- 5.6.2.4. Germany Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.6.3. Spain
- 5.6.3.1. Key Country Dynamics
- 5.6.3.2. Competitive Scenario
- 5.6.3.3. Regulatory Framework
- 5.6.3.4. Spain Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.6.4. France
- 5.6.4.1. Key Country Dynamics
- 5.6.4.2. Competitive Scenario
- 5.6.4.3. Regulatory Framework
- 5.6.4.4. France Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.6.5. Italy
- 5.6.5.1. Key Country Dynamics
- 5.6.5.2. Competitive Scenario
- 5.6.5.3. Regulatory Framework
- 5.6.5.4. Italy Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.6.6. Denmark
- 5.6.6.1. Key Country Dynamics
- 5.6.6.2. Competitive Scenario
- 5.6.6.3. Regulatory Framework
- 5.6.6.4. Denmark Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.6.7. Sweden
- 5.6.7.1. Key Country Dynamics
- 5.6.7.2. Competitive Scenario
- 5.6.7.3. Regulatory Framework
- 5.6.7.4. Sweden Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.6.8. Norway
- 5.6.8.1. Key Country Dynamics
- 5.6.8.2. Competitive Scenario
- 5.6.8.3. Regulatory Framework
- 5.6.8.4. Norway Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.7. Asia Pacific
- 5.7.1. Japan
- 5.7.1.1. Key Country Dynamics
- 5.7.1.2. Competitive Scenario
- 5.7.1.3. Regulatory Framework
- 5.7.1.4. Japan Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.7.2. China
- 5.7.2.1. Key Country Dynamics
- 5.7.2.2. Competitive Scenario
- 5.7.2.3. Regulatory Framework
- 5.7.2.4. China Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.7.3. India
- 5.7.3.1. Key Country Dynamics
- 5.7.3.2. Competitive Scenario
- 5.7.3.3. Regulatory Framework
- 5.7.3.4. India Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.7.4. South Korea
- 5.7.4.1. Key Country Dynamics
- 5.7.4.2. Competitive Scenario
- 5.7.4.3. Regulatory Framework
- 5.7.4.4. South Korea Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.7.5. Thailand
- 5.7.5.1. Key Country Dynamics
- 5.7.5.2. Competitive Scenario
- 5.7.5.3. Regulatory Framework
- 5.7.5.4. Thailand Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.7.6. Australia
- 5.7.6.1. Key Country Dynamics
- 5.7.6.2. Competitive Scenario
- 5.7.6.3. Regulatory Framework
- 5.7.6.4. Australia Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.8. Latin America
- 5.8.1. Brazil
- 5.8.1.1. Key Country Dynamics
- 5.8.1.2. Competitive Scenario
- 5.8.1.3. Regulatory Framework
- 5.8.1.4. Brazil Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.8.2. Argentina
- 5.8.2.1. Key Country Dynamics
- 5.8.2.2. Competitive Scenario
- 5.8.2.3. Regulatory Framework
- 5.8.2.4. Argentina Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.9. MEA
- 5.9.1. MEA Cardiac Rhythm Management Devices Market, 2018 - 2030 (USD Million)
- 5.9.2. South Africa
- 5.9.2.1. Key Country Dynamics
- 5.9.2.2. Competitive Scenario
- 5.9.2.3. Regulatory Framework
- 5.9.2.4. South Africa Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.9.3. Saudi Arabia
- 5.9.3.1. Key Country Dynamics
- 5.9.3.2. Competitive Scenario
- 5.9.3.3. Regulatory Framework
- 5.9.3.4. Saudi Arabia Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.9.4. UAE
- 5.9.4.1. Key Country Dynamics
- 5.9.4.2. Competitive Scenario
- 5.9.4.3. Regulatory Framework
- 5.9.4.4. UAE Market Estimates and Forecasts 2018 To 2030 (USD Million)
- 5.9.5. Kuwait
- 5.9.5.1. Key Country Dynamics
- 5.9.5.2. Competitive Scenario
- 5.9.5.3. Regulatory Framework
- 5.9.5.4. Kuwait Market Estimates and Forecasts 2018 To 2030 (USD Million)
Chapter 6. Competitive Landscape
- 6.1. Recent Developments & Impact Analysis, By Key Market Participants
- 6.2. Company /Competition Categorization
- 6.3. Vendor Landscape
- 6.3.1. List of Key Distributors And Channel Partners
- 6.3.2. Key Customers
- 6.3.3. Key Company Market Share Analysis, 2023
- 6.3.4. Physio-Control, Inc.
- 6.3.4.1. Overview
- 6.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.3.4.3. Product Benchmarking
- 6.3.4.4. Strategic Initiatives
- 6.3.5. Medtronic, plc
- 6.3.5.1. Overview
- 6.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.3.5.3. Product Benchmarking
- 6.3.5.4. Strategic Initiatives
- 6.3.6. ABBOTT
- 6.3.6.1. Overview
- 6.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.3.6.3. Product Benchmarking
- 6.3.6.4. Strategic Initiatives
- 6.3.7. Boston Scientific Corporation
- 6.3.7.1. Overview
- 6.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.3.7.3. Product Benchmarking
- 6.3.7.4. Strategic Initiatives
- 6.3.8. Schiller
- 6.3.8.1. Overview
- 6.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.3.8.3. Product Benchmarking
- 6.3.8.4. Strategic Initiatives
- 6.3.9. Koninklijke Philips N.V
- 6.3.9.1. Overview
- 6.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.3.9.3. Product Benchmarking
- 6.3.9.4. Strategic Initiatives
- 6.3.10. Biotronik
- 6.3.10.1. Overview
- 6.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.3.10.3. Product Benchmarking
- 6.3.10.4. Strategic Initiatives
- 6.3.11. Progetti Srl
- 6.3.11.1. Overview
- 6.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.3.11.3. Product Benchmarking
- 6.3.11.4. Strategic Initiatives
- 6.3.12. Zoll Medical Corporation
- 6.3.12.1. Overview
- 6.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.3.12.3. Product Benchmarking
- 6.3.12.4. Strategic Initiatives
- 6.3.13. LivaNova Plc
- 6.3.13.1. Overview
- 6.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 6.3.13.3. Product Benchmarking
- 6.3.13.4. Strategic Initiatives